Pharmathene Inc (PIP) 2.89 $PIP PharmAthene Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pharmathene Inc (PIP) 2.89 $PIP

PharmAthene Announces Receipt of Payments from SIGA
PR Newswire - Fri Sep 16, 6:33AM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced it has received a series of payments from SIGA Technologies, Inc. totaling $90 million over the past month. Combined with $25 million in previous payments, PharmAthene has now received a total of $115 million plus $6.6 million of interest in partial payment of the SIGA judgement. Under the approved reorganization plan, SIGA has until November 30, 2016 to pay the remaining balance of $93.7 million plus interest.
PIP: 2.89 (-0.02)

PharmAthene Withdraws Protest Against HHS Over Anthrax Vaccine Bidding Process
PR Newswire - Thu Aug 25, 4:00PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced that after discussions with the Biomedical Advanced Research and Development Authority (BARDA) the Company has withdrawn the protest filed on August 5, 2016.
PIP: 2.89 (-0.02)

PharmAthene Files Protest Against HHS Over Anthrax Vaccine Bidding Process
PR Newswire - Fri Aug 05, 11:56AM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today filed a formal protest against the Department of Health and Human Services, challenging its solicitation for a next-generation Anthrax vaccine provider.
PIP: 2.89 (-0.02)

PharmAthene Reports Second Quarter 2016 Financial and Operational Results
PR Newswire - Thu Aug 04, 3:17PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the second quarter of 2016.
PIP: 2.89 (-0.02)

PharmAthene Reports First Quarter 2016 Financial and Operational Results
PR Newswire - Mon May 09, 4:21PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the first quarter of 2016.
PIP: 2.89 (-0.02)

Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene
PR Newswire - Thu Dec 24, 7:00AM CST
PharmAthene, Inc. (NYSE MKT: PIP) announced today that the Delaware Supreme Court affirmed the Delaware Court of Chancery's decision to award PharmAthene lump sum expectation damages for the value of PharmAthene's lost profits for SIGA's smallpox antiviral, Tecovirimat. The Delaware Court of Chancery awarded PharmAthene $113 million in expectation damages plus interest and other costs, which if calculated based on the original decision (and including post-judgment interest) would provide for an estimated total of approximately $205 million. PharmAthene's ability to collect a monetary judgment, including post-petition interest, from SIGA remains subject to further proceedings in the Federal Bankruptcy Court. SIGA has filed a reorganization plan with the Court that provides for among other things, the process by which PharmAthene's judgment may be satisfied, but that plan has not been approved by the Bankruptcy Court and remains subject to change, withdrawal or rejection by the Court. A copy of the Delaware Supreme Court decision is available at: http://courts.delaware.gov/opinions/download.aspx?ID=234170.
PIP: 2.89 (-0.02)

SIGA Announces That Delaware Supreme Court Affirms Court of Chancery Opinion
BusinessWire - Wed Dec 23, 3:32PM CST
SIGA Technologies, Inc. a company specializing in the commercialization of solutions for serious unmet medical needs and biothreats, today announced that the Delaware Supreme Court affirmed the prior Court of Chancery Opinion in which the court awarded PharmAthene, Inc. approximately $195 million, including pre-judgment interest up to January 15, 2015.
PIP: 2.89 (-0.02)

PharmAthene Reports that SIGA has Filed its Reorganization Plan to Exit from Bankruptcy
PR Newswire - Tue Dec 15, 5:20PM CST
PharmAthene, Inc. (NYSE MKT: PIP) reported today that SIGA Technologies, Inc. filed with the U.S. Bankruptcy Court for the Southern District of New York a reorganization plan that sets out the terms and conditions under which SIGA will seek to exit from bankruptcy. The plan filed was negotiated between SIGA and the Statutory Creditor's Committee of which PharmAthene is a member. The plan is subject to approval by the bankruptcy court, on a timeline to be determined. A copy of the plan is available at: https://cases.primeclerk.com/siga/Home-Downlo...&id2=0.
PIP: 2.89 (-0.02)

PharmAthene Adopts Stockholder Rights Plan in an Effort to Protect Net Operating Loss Carryforwards
PR Newswire - Wed Nov 25, 3:11PM CST
PharmAthene, Inc. (NYSE MKT: PIP) announced today that its Board of Directors has adopted a stockholder rights plan (Rights Plan) in an effort to preserve the value of its net operating loss carryforwards (NOLs) under Section 382 of the Internal Revenue Code (Code).
PIP: 2.89 (-0.02)

PharmAthene Reports Third Quarter 2015 Financial and Operational Results
PR Newswire - Fri Nov 06, 3:00PM CST
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological threats, today reported its financial and operational results for the third quarter of 2015.
PIP: 2.89 (-0.02)

Anthrax - Pipeline Review, H2 2015
M2 - Fri Nov 06, 8:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3bjw94/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Altimmune, Inc. - Aphios Corporation - Aradigm Corporation - Bavarian Nordic A/S - Bristol-Myers Squibb Company - Cellceutix Corporation - ContraFect Corporation - Dynavax Technologies Corporation - Elusys Therapeutics, Inc. - Emergent BioSolutions Inc. - Green Cross Corporation - Grifols, S.A. - Hawaii Biotech, Inc. - iBio, Inc. - Innovative Biologics, Inc. - Microbiotix, Inc. - NanoBio Corporation - Oragenics, Inc. - PaxVax - Pfenex Inc. - PharmAthene, Inc. - Protein Potential, LLC - ProThera Biologics, LLC. - PsiOxus Therapeutics Limited - Soligenix, Inc. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - United Therapeutics Corporation - VLP Biotech, Inc. For more information visit http://www.researchandmarkets.com/research/3bjw94/anthrax
DVAX: 11.41 (-0.21), TTPH: 3.83 (-0.04), ADRO: 14.54 (-0.25), EBS: 28.36 (-0.38), UTHR: 127.21 (+0.20), BMY: 56.48 (+0.06), PFNX: 9.10 (-0.25), PIP: 2.89 (-0.02), IBIO: 0.56 (unch), OGEN: 0.53 (-0.02)

PharmAthene Announces Conclusion of Oral Arguments In Its Litigation Against SIGA
PR Newswire - Wed Oct 07, 4:28PM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced that oral arguments in SIGA's appeal and PharmAthene's cross-appeal of the Delaware Court of Chancery's January 15, 2015 Final Order and Judgment in PharmAthene's litigation against SIGA took place in the Delaware Supreme Court today at 11:00 am ET. The oral argument proceedings may be viewed online at: http://livestream.com/DelawareSupremeCourt/ev.../101331469
PIP: 2.89 (-0.02)

Immunovaccine and PharmAthene Sign Exclusive Worldwide License Agreement to Develop and Commercialize an Anthrax Vaccine Formulated in DepoVax(TM)
Marketwired - Wed Jul 08, 6:05AM CDT
Immunovaccine Inc. (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, announced today that it has entered into an exclusive worldwide license agreement with PharmAthene, Inc. (NYSE MKT: PIP) to develop and commercialize a Recombinant Protective Antigen Anthrax vaccine (rPA) candidate utilizing Immunovaccine's proprietary DepoVax(TM) vaccine platform.
IMV.TO: 0.78 (-0.02), PIP: 2.89 (-0.02)

US Military Accidentally Ships Live Anthrax via FedEx; These Are the Stocks to Watch in Its Wake
ACCESSWIRE - Mon Jun 01, 10:18AM CDT
WINDSOR, ON / ACCESSWIRE / June 1, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known, Biotech stocks making news and subsequent market moves.
FDX: 174.39 (+0.73), ROSG: 0.91 (unch), PIP: 2.89 (-0.02), NSPH: 1.69 (-0.01)

SIGA Technologies Receives NASDAQ Delisting Notification
BusinessWire - Wed Mar 18, 3:52PM CDT
SIGA Technologies, Inc. ("SIGA" , a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced that it received a letter today from the Hearings Advisor for The NASDAQ Stock Market LLC ("NASDAQ" , indicating that the NASDAQ Hearings Panel has determined to delist the shares of the Company from the NASDAQ Stock Market and accordingly, suspend trading in the Company's shares effective at the open of business on March 20, 2015. SIGA expects its shares to continue to trade on the OTC Markets under the "SIGAQ" symbol.
PIP: 2.89 (-0.02)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 0

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 128

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Movement Elevates a Longtime Insider as Its New CEO

Updated Category News Views 81

Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 158

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Yunnan Tin’s AI Materials Push Has Real Operating Teeth

Updated Category News Views 66

Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 30

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
Ajman Forum Puts Trust at the Center of Crisis Media

Updated Category News Views 82

Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...

Continue Reading
NKT’s Q3 Margin Holds Up as Capacity Spending Bites

Updated Category News Views 119

Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...

Continue Reading
Caliway's China Clearance Speeds CBL-514's Next Test

Updated Category News Views 18

China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...

Continue Reading

Top 5 Most Recently Viewed Articles

Immuron Advances IMM-529 Development Following FDA Feedback

Updated Category News Views 289

Immuron Charts Path for Phase 2 Trial of IMM-529 Key Highlights Immuron concludes an important pre-IND meeting with the FDA regarding IMM-529, aimed at combating Clostridioides difficile infection (CDI). Previous clinical trials highlight the necessity for ongoing development of IMM-529. The company plans to submit an IND application for IMM-529 in the first half of 2025.

Continue Reading
Enefit Green to Host Webinars for Unveiling 2024 Results

Updated Category News Views 123

Join Enefit Green's Upcoming Webinars on 2024 Results Enefit Green is set to announce its Q4 and annual unaudited results for 2024. The special reveal will occur shortly after the publication of the report, allowing shareholders and investors to gain critical insights into the company's financial standing. Webinar Schedule and Details The webinars will be hosted on the...

Continue Reading
Intapp's Encouraging Earnings Fuel Stock Surge Amid Market Momentum

Updated Category News Views 197

Intapp's Strong Earnings Report Captivates Investors On a positive note for investors, U.S. stocks saw an uplifting day, with the Dow Jones index climbing approximately 250 points. The highlight of the day was the impressive performance of Intapp, Inc. Shares of Intapp, Inc. (NASDAQ: INTA) experienced a sharp increase following the company's announcement of...

Continue Reading
NewAmsterdam Pharma's Upcoming Conference Participation for 2024

Updated Category News Views 229

NewAmsterdam Pharma Announces Conference Participation NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is gearing up for an exciting lineup of presentations at key medical and investor conferences. As a leader in developing innovative oral therapies for cardiovascular disease, NewAmsterdam is set to share groundbreaking research findings and engage with stakeholders in...

Continue Reading
John Hancock Funds Announce Monthly Distribution Updates

Updated Category News Views 366

Monthly Distribution Announcements from John Hancock Funds John Hancock has announced important updates regarding the distributions for its closed-end funds. These monthly distributions aim to provide returns to investors, ensuring they receive value from their investments in a timely manner. Details of the Monthly Distribution Declaration Key Dates Recently, the board of...

Continue Reading